BioCentury
ARTICLE | Company News

Ascendis, United Therapeutics deal

October 1, 2012 7:00 AM UTC

United Therapeutics received exclusive rights to use Ascendis' TransCon technology in prostacyclin-related products to treat pulmonary arterial hypertension (PAH). United Therapeutics plans to develop a self-injectable version of treprostinil for PAH. Ascendis and United will collaborate on development, though United Therapeutics said it is ultimately responsible for development. United Therapeutics will have worldwide commercialization rights to products resulting from the deal. United Therapeutics declined to disclose financial details. Ascendis could not be reached for details. ...